Blinatumomab vs historic standard‐of‐care treatment for minimal residual disease in adults with B‐cell precursor acute lymphoblastic leukaemia-Reference-Cited by-同舟云学术

Blinatumomab vs historic standard‐of‐care treatment for minimal residual disease in adults with B‐cell precursor acute lymphoblastic leukaemia

Published:2020-01-24 Issue:4 Volume:104 Page:299-309
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Gökbuget Nicola¹^ORCID,Dombret Hervé²,Giebel Sebastian³,Brüggemann Monika⁴,Doubek Michael⁵,Foa Robin⁶,Hoelzer Dieter⁷,Kim Christopher⁸,Martinelli Giovanni⁹,Parovichnikova Elena¹⁰,Maria Ribera Josep¹¹,Schoonen Marieke¹²,Tuglus Catherine¹³,Zugmaier Gerhard¹⁴,Bassan Renato¹⁵

Affiliation:

1. University Hospital Goethe University Frankfurt Germany

2. Hôpital Saint‐Louis University Paris Diderot Paris France

3. Maria Sklodowska‐Curie Institute—Oncology Center Gliwice Poland

4. University Hospital Schleswig‐Holstein Kiel Germany

5. University Hospital and CEITEC Masaryk University Brno Czech Republic

6. ‘Sapienza’ University of Rome Rome Italy

7. J.W. Goethe University Hospital Frankfurt Germany

8. Center for Observational Research Amgen Inc Thousand Oaks CA USA

9. Policlinico S Orsola Istituto Seragnoli Bologna Italy

10. National Research Center for Hematology Moscow Russia

11. ICO‐Hospital Germans Trias i Pujol Jose Carreras Research Institute Barcelona Spain